(NASDAQ: PAHC) Phibro Animal Health's forecast annual revenue growth rate of 4.12% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8.49%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.61%.
Phibro Animal Health's revenue in 2026 is $1,518,093,000.On average, 5 Wall Street analysts forecast PAHC's revenue for 2027 to be $65,327,979,227, with the lowest PAHC revenue forecast at $62,607,671,826, and the highest PAHC revenue forecast at $67,439,262,583. On average, 5 Wall Street analysts forecast PAHC's revenue for 2028 to be $67,601,668,995, with the lowest PAHC revenue forecast at $64,637,751,976, and the highest PAHC revenue forecast at $70,159,569,984.
In 2029, PAHC is forecast to generate $69,509,944,336 in revenue, with the lowest revenue forecast at $66,789,636,935 and the highest revenue forecast at $71,580,626,089.